

Contents

Contributors	<i>page</i> vii
Preface	xi
SECTION I: INFRASTRUCTURE	
1 The U.S. Food and Drug Administration and the regulation of small molecules for orphan diseases	3
Marlene E. Haffner and Tan T. Nguyen	
2 The Office of Rare Diseases Research: Serving a coordinating function at the National Institutes of Health	19
Stephen C. Groft	
3 Introduction to pharmacokinetics and pharmacodynamics	35
Juan J. L. Lertora and Konstantina M. Vanevski	
SECTION II: COFACTORS	
4 Biotin and biotin-responsive disorders	57
Kirit Pindolia and Barry Wolf	
5 Cobalamin treatment of methylmalonic acidemias	68
Hans C. Andersson	
6 Sapropterin treatment of phenylketonuria	76
Barbara K. Burton	
7 L-carnitine therapy in primary and secondary carnitine deficiency disorders	86
Susan C. Winter, Brian Schreiber, and Neil R. M. Buist	
SECTION III: UTILIZATION OF ALTERNATIVE PATHWAYS	
8 Cysteamine treatment of nephropathic cystinosis	101
Jess G. Thoene	
9 Nitisinone use in hereditary tyrosinemia and alkaptonuria	114
Wendy J. Introne, Kevin J. O'Brien, and William A. Gahl	
10 Alternative waste nitrogen disposal agents for urea cycle disorders	135
Gregory M. Enns	

11	PDMP-based glucosylceramide synthesis inhibitors for Gaucher and Fabry diseases	153
	James A. Shayman	
12	Betaine treatment for the homocystinurias	173
	Amy Lawson-Yuen and Harvey L. Levy	
SECTION IV: METAL ION THERAPY		
13	Zinc and tetrathiomolybdate for the treatment of Wilson disease	185
	George J. Brewer	
14	Small copper complexes for treatment of acquired and inherited copper deficiency syndromes	202
	Stephen G. Kaler	
	Index	213

Color plates follow page 130.